Mechanism study of hNPC01 neural progenitor cell grafting therapy in a rat ischemic stroke model was published in Nature Communications

Hopstem Biotechnology at 2024 CASSS CGPT Symposium

Hopstem to Showcase hNPC01 Clinical Data at 2024 ASGCT Annual Meeting in Baltimore

hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by FDA

hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by CFDA